As of 13:59 on March 17, 2025, the Innovative Pharmaceutical Enterprise ETF (560900) rose 0.51%, with an intraday turnover of 2.1161 million yuan and a turnover rate of 5.53%. The CSI Innovative Drug Industry Index (931152) rose 0.22%, the constituent stocks Rongchang Biotech (688331) rose 11.72%, Kangtai Biotech (300601) rose 4.49%, Baili Tianheng (688506) rose 3.77%, Tebao Biotech (688278) rose 3.60%, and Zhixiang Jintai (688443) rose 2.93%.

Guojin Securities believes that it is recommended to continue to implement the two main lines of pharmaceutical investment in AI medicine + innovative drugs in 2025. In addition, the recent A-share and Hong Kong-listed pharmaceutical companies are about to enter the annual report window, and it is expected that the pharmaceutical sector is expected to usher in the overall performance reversal of the industry after the first quarter of the annual report. With the warming of policies and sentiment, the marginal changes in sectors such as brain-computer interface, consumer healthcare, and online pharmaceutical retail are obvious, which deserves more attention.

The

ETF closely tracks the CSI Innovative Pharmaceutical Industry Index, which selects no more than 50 of the most representative securities of listed companies from the securities of listed companies whose main business involves the research and development of innovative drugs as the index sample to reflect the overall performance of the securities of listed companies in the innovative drug industry.

In addition, JPMorgan's related ETFs include JPMorgan Hang Seng Technology ETF (QDII) (513890), which is a leading technology company in Hong Kong, JPMorgan CSI Carbon Neutral 60 ETF (560960), which captures investment opportunities in green China, and JPMorgan MSCI China A-share ETF (515770), which is a core asset in China.

With the rise of a new wave of AI-driven technology, J.P. Morgan Asset Management has integrated its "Global Vision Investment Technology" product line, from active management to passive investment products, to help investors deploy high-quality technology companies from a global perspective and grasp the investment opportunities under the tide of the times.

In terms of active management, J.P. Morgan Emerging Power Fund (Class A: 377240 Class C: 014642) strives to grasp emerging industry trends from a long-term perspective; J.P. Morgan Smart Connect Fund (Class A: 001313 Class C: 016919) focuses on opportunities in AI-related fields; J.P. Morgan Power Select Fund (Class A: 006250 Class C: 013137) focuses on the new energy vehicle industry chain, humanoid robots and other fields; J.P. Morgan Smart Growth Fund (Class A: 008314 Class C: 008315), which lays out A+H high-quality growth companies; J.P. Morgan Pacific Fund (PRC RMB Hedged (cumulative) 968061, PRC RMB (cumulative) 968962, PRC USD share (cumulative) 968063) selects high-quality technology companies in the Pacific region.

In terms of passive investment, J.P. Morgan Hang Seng Technology ETF (QDII) (stock code: 513890, Connect Class A: 018577, Connect Class C: 018578) provides a one-click layout of Hong Kong stock technology assets; J.P. Morgan CSI Innovative Pharmaceutical Industry ETF (stock code: 560900) one-click layout of China's innovative pharmaceutical companies; Morgan NASDAQ 100 Index Fund (QDII) (RMB A:019172 RMB C:019173 USD A:019174 USD C: 019175) is a one-click layout of global technology leaders.